Assembly Biosciences Inc (NAS:ASMB)

$ 16.26 0.41 (2.59%) Market Cap: 103.18 Mil Enterprise Value: -5.56 Mil PE Ratio: 0 PB Ratio: 2.97 GF Score: 39/100

Assembly Biosciences Inc Extraordinary Shareholders Meeting Transcript
Jan 31, 2024
Assembly Biosciences Inc Partnership with Gilead Sciences Inc to Develop Next-Generation Antiviral Therapeutics Call Transcript
Oct 17, 2023
Assembly Biosciences Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Assembly Biosciences Inc Annual Shareholders Meeting Transcript
May 25, 2023
Assembly Biosciences Inc HSV-2 and Transplant-Associated Herpesviruses Research - Corporate Call Transcript
Aug 31, 2022
Assembly Biosciences Inc IFNAR (Interferon-a Receptor Agonist) Research - Corporate Call Transcript
Jul 26, 2022
Assembly Biosciences Inc HBV/HDV Entry Inhibitor Research - Corporate Call Transcript
Mar 31, 2022
Assembly Biosciences Inc Annual Shareholders Meeting Transcript
May 20, 2021
Assembly Biosciences Inc Earnings Call Transcript
Feb 25, 2021

$66.36 (-1.95%)

Earnings
Assembly Biosciences, Inc. - Special Call Transcript
Nov 05, 2020
Assembly Biosciences, Inc. - Special Call Transcript
Jul 20, 2020
Assembly Biosciences Inc Annual Shareholders Meeting Transcript
Jun 11, 2020
Assembly Biosciences Inc to Discuss HBV Portfolio Progress Call Transcript
May 07, 2020
Assembly Biosciences, Inc. - Special Call Transcript
Nov 11, 2019
Assembly Biosciences, Inc Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019 Call Transcript
Apr 15, 2019

Assembly Biosciences, Inc. - Special Call Transcript

Jul 20, 2020 / 12:30PM GMT

Release Date Price: $324.48 (+10.46%)

Transcript

Operator

Good morning, and welcome to the Assembly Biosciences conference call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to hand the call over to Lauren Glaser, Senior Vice President of Investor Relations and Corporate Affairs for Assembly. Please go ahead.

Lauren Glaser

Assembly Biosciences, Inc. - SVP of IR & Corporate Affairs

Thank you, Bridget. Good morning, and thank you for joining us on such short notice. Today's announcement of our strategic collaboration with BeiGene is an exciting and significant milestone for Assembly. This collaboration provides a strong foundation to accelerate the development in China of our hepatitis B portfolio, which currently consists of 3 clinical stage core inhibitors: ABI-H0731 and ABI-H2158, which are in ongoing Phase II clinical trials, and ABI-H3733, which is in Phase I development.

The press release and the slides we will refer to during the call are available in the News and Events section of our corporate website at

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.